在获得美国食品药品监督管理局的许可后，IceCure Medical Ltd. 的乳腺癌冷冻消融系统在美国的商业装机量实现了显著扩张。该公司报告称，其活跃的商业装机基数实现了高达 70% 的增长，这一数据凸显了市场对其创新疗法的强劲需求与快速接纳。
这一增长标志着该技术在美国临床实践中的渗透率加速提升。冷冻消融作为一种微创治疗方案，正日益成为乳腺癌患者的重要选择之一。装机量的激增不仅反映了医疗机构的采购意愿，也预示着该疗法未来可能惠及更广泛的患者群体。
公司业绩的这一积极进展，为其后续的市场拓展和商业化进程奠定了坚实基础。随着装机网络的扩大，IceCure 有望进一步巩固其在肿瘤微创介入治疗领域的市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.